Published in final edited form as:

Chem Commun (Camb). 2020 January 23; 56(7): 1085–1088. doi:10.1039/c9cc08752d.

Elastase-triggered H₂S delivery from polymer hydrogels

Mingjun Zhou^{†,a}, Yun Qian^{†,a}, Yumeng Zhu^a, John Matson^{*,a}

^aDepartment of Chemistry and Macromolecules Innovation Institute, Virginia Tech, Blacksburg, Virginia 24061, United States.

Abstract

We report an elastase-responsive, H₂S-releasing hydrogel prepared by covalently crosslinking a mixture of carboxymethylcellulose and poly(ethylene glycol) with an elastase-degradable peptide functionalized with an H₂S-releasing *S*-aroylthiooxime (SATO) unit. Addition of elastase triggered a gel-to-sol transition, which exposed SATOs, leading to more and longer H₂S release compared to untriggered gels.

Graphical Abstract

Since the biological roles of H₂S were first discovered in 1996, its physiological functions have been investigated and explained, eventually leading to its recognition as a gasotransmitter.¹⁻³ Joining NO and CO in this group of endogenously produced privileged signalling molecules,^{4,5} H₂S has shown potential for treating diseases due to its pro-angiogenic, antioxidant, anti-apoptotic, and anti-inflammatory properties.⁶⁻⁸ Among the beneficial effects of physiological levels of H₂S, its ability to reduce inflammation is particularly intriguing given the increasing awareness of the role of inflammation in a variety of diseases, including cancer, Alzheimer's, arthritis, diabetes, stroke, and cardiovascular disease.⁹ H₂S inhibits inflammation through several proposed mechanisms, including increased blood flow via vasodilation,¹⁰ phosphodiesterase inhibition,¹¹

jbmatson@vt.edu.

[†]These two authors contributed equally.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here].
See DOI: [10.1039/x0xx00000x](https://doi.org/10.1039/x0xx00000x)

cytoprotective effects from the opening of K_{ATP} channels,¹² and as a mediator in upregulating the adherence and migration of leukocytes.¹³ Due to its physiological functions, H_2S has been studied as a potential treatment for chronic diseases with recurring inflammation, such as lung disease,¹⁴ ulcers,¹⁵ and edemas.¹⁶

For many diseases, enzymes are important in their pathology, and elevated enzyme activity levels can contribute to the diagnosis of certain conditions.¹⁷ Beyond disease detection, the ability of enzymes to selectively make and break bonds under mild conditions makes them attractive triggers in the development of responsive materials, especially for drug release.^{18,19} Human neutrophil elastase (HNE) is a serine protease, secreted by neutrophils responding to inflammation.²⁰ Cleaving peptides/proteins selectively at the carbonyl side of Val or Ala residues, HNE has been employed as a trigger for smart materials.²¹ By degrading the peptide/protein components of synthetic hydrogels, HNE can enable localized drug delivery through triggering a gel-to-sol transition.^{22,23} Due to the links between inflammation, HNE, and H_2S , we became interested in developing an HNE-triggered, H_2S -releasing hydrogel, with the goal of evaluating its potential for treating chronic diseases with recurring inflammation. Such a hydrogel would ideally remain stable in the absence of inflammation, but release H_2S when HNE activity increases in response to inflammation.

We envisioned that an HNE-responsive hydrogel could be prepared by crosslinking a biocompatible polymer with HNE-degradable peptides. Peptides are convenient biodegradable building blocks for fabricating hydrogels due to their tunable chemistry and easy synthesis. Our lab has previously reported H_2S -releasing peptide hydrogels based on physical crosslinking.^{24,25} However, we chose covalently crosslinked hydrogels for this project due to their stability to changes in pH and ionic strength, as well as their tunable stiffness through control of crosslinking density.²⁶ Only by chemically breaking the crosslinks can covalently crosslinked hydrogels be degraded. Here we describe the design and construction of peptide-crosslinked polymer hydrogels with covalently attached H_2S -donating groups. We hypothesized that degradation of the gel by HNE would initiate a gel-to-sol transition, exposing buried and unreactive H_2S -donating groups unable to react in the gel state and leading to H_2S release. Additionally, we examined the H_2S -releasing profiles of hydrogels with varying stiffnesses. Finally, we assessed their ability to protect cardiomyocytes from the harmful effects of doxorubicin (Dox).

Our synthetic route to an HNE-responsive, H_2S -releasing hydrogel is shown in Scheme 1. We started by crosslinking a 2 wt% solution of carboxymethyl cellulose (CMC) with the peptide-aldehyde **FBA-VKVKVK** (FBA = 4-formylbenzamide) using EDC/NHS coupling chemistry. However, the resulting hydrogel was quite stiff and did not undergo a gel-sol transition after exposure to HNE. To increase compliance, we lowered the amount of CMC by replacing a portion of it with poly(ethylene glycol) with carboxylic acids at each end (HOOC-PEG-COOH). We found the lowest amount of CMC required to form a robust, self-supporting gel was 35 mol% (carboxylate count, abbreviated as 35% CMC). After gelation and swelling several times to remove reaction byproducts, we analysed the rheology of this peptide-crosslinked CMC-PEG hydrogel (Fig. S2), which showed a stable storage modulus (G') of 1600 Pa at low frequencies (<5 Hz; 1% strain) with $G' > G''$ (G'' = loss modulus). Following lyophilization, dry hydrogel powder was reacted with *S*-

benzoylthiohydroxylamine (SBTHA) to convert aldehyde groups into *S*-aroylthiooximes (SATO), which release H₂S upon reaction with thiols such as Cys.²⁷ Elemental analysis of the dry SATO-hydrogel showed a sulfur loading of 1.7 wt%, corresponding to a SATO loading of 0.53 mmol/g and a near-quantitative SBTHA coupling conversion. Scanning electron microscopy (SEM) images showed no significant morphology changes between lyophilized hydrogels before and after the SBTHA coupling (Figure S6).

We first used matrix-assisted laser desorption ionization–tandem time of flight mass spectrometer (MALDI-TOF) to investigate the degradation of the peptide-aldehyde **FBA-VKVKVK** in solution with HNE. We observed the onset of degradation within 30 min, and it continued over 24 h. As expected based on elastase specificity for Val residues, cleavage of the amide bonds on the C-terminal sides of the Val residues (red bonds in Scheme 1) occurred preferentially, although the Val amide bond closest to the N-terminus remained intact, likely due to the presence of FBA (Fig. S3).

Next, we investigated H₂S release from the SATO-hydrogel (35% CMC) with different concentrations of HNE. We used a specially designed vial with an inner well sealed with a polymer membrane, reported previously, that prevented Cys, which is added as a trigger, from interfering with the analysis of H₂S release.²⁸ In this type of open-air experiment using an H₂S sensitive electrode probe, the H₂S release profile reaches a maximum peaking time and peaking concentration, after which the H₂S concentration falls over time as the rate of H₂S volatilization and oxidation exceeds the rate of H₂S generation. We hypothesized that with a higher HNE concentration, the cleavage of the peptide crosslinker would accelerate, degrading the hydrogel and leading to a faster release of H₂S due to exposure of the buried SATO groups.

The release profiles and their corresponding peaking times and peaking concentrations for the 35% CMC hydrogel are shown in Fig. 1A and Table S1. Without HNE, H₂S reached a peaking concentration of 0.6 ± 0.2 μ M and a peaking time of 240 ± 20 min. Because there is no degradation and no gel-sol transition under these conditions (Fig. S4), release in this experiment is likely from SATO groups near the hydrogel surface. With 23 μ g/mL HNE (defined here as 1 unit or 1 HNE), the peaking H₂S concentration increased to 0.8 ± 0.1 μ M, with an increased peaking time of 354 ± 4 min. The same trend applied when 2 units of HNE were added, with further increases in both of peaking concentration (1.4 ± 0.3 μ M) and peaking time (580 ± 50 min).

We expected that more HNE would lead to faster H₂S release, indicated by a shorter peaking time, but the opposite effect was observed—more HNE led to prolonged H₂S release and in larger amounts. These results indicate that there are two types of SATO groups in the hydrogels: 1) surface SATO groups, which can be easily accessed by Cys and release H₂S; and 2) interior SATO groups, which are initially encapsulated inside the hydrogel matrix. Only by cleaving the peptide crosslinker and degrading the hydrogel are the buried SATO groups exposed to Cys. Considering the HNE degradation of the peptide crosslinker is slow based on the MALDI-TOF results (Figure S3), and the peaking time of small molecule SATOs is rather short (generally 10–80 min),²⁷ HNE degradation is likely the rate-determining step in H₂S release, rather than the Cys attack. Therefore, in the initial stage, the

H₂S release was mostly from the surface SATO groups, which is why there was no significant difference among the three curves. However, with more HNE, a greater extent of hydrogel degradation leads to more total H₂S release. This conclusion was confirmed by visual observations, where 24 h after Cys addition, the hydrogel treated with 2 HNE was fully degraded, while the hydrogel treated with only Cys (no HNE) remained intact, and the hydrogel treated with 1 HNE was partially degraded.

To further confirm that the difference in the curves in Fig. 1A originated from HNE degradation, we synthesized a control hydrogel crosslinked by a non-HNE degradable peptide, **FBA-GKGGK**, with the rest of the synthetic route unchanged. As shown in Fig. 1B, with HNE (1 unit) the release profile was even slightly lower than the one without HNE, with similar peaking times. The difference in peaking concentration is due to variability in the probe and experimental conditions. This result supports the proposed HNE degradation effect.

Based on our conclusion that there exist both surface SATO groups, which are accessible to Cys without HNE, and interior SATO groups, which only release H₂S after HNE-triggered degradation of the gel, we were interested in the H₂S-releasing behavior of these hydrogels after consuming the surface SATO groups. Thus, we designed a release experiment in which we treated a hydrogel sample only with Cys for 24 h, allowing the surface SATO groups to react completely. We then added either Cys alone or HNE and Cys. We envisioned that adding only Cys after 24 h would show no increase in H₂S concentration because all surface SATO groups would have been consumed. In contrast, we expected that adding Cys and HNE would generate more H₂S because interior SATO groups would be available to react with Cys to release H₂S after hydrogel degradation.

The results from this experiment are shown in Fig. 2A. The black curve shows the first 24 h of the experiment, when the gel was treated only with Cys. It showed a similar peaking time and concentration to the black curve shown in Fig. 1A. After 24 h, the H₂S concentration nearly reached a plateau, indicating most of the surface SATO groups were consumed. Baseline fluctuations in the instrument over several hours prevent a complete return to baseline, so H₂S release is considered complete when a plateau is reached. After 24 h, HNE (2 units) was added to the reaction mixture to trigger the gel-sol transition and expose the interior SATO groups to Cys. As shown in the blue curve, H₂S release resumed with a peaking time and concentration similar to the blue curve Fig. 1A. The pink curve, where additional Cys but no HNE was added, confirmed that the change in H₂S release was not from the addition of Cys.

Besides confirming the existence of surface and interior SATO groups, this experiment was also designed to mimic the process to treat chronic diseases with recurring inflammation. The black and pink curves mimic the process if the hydrogel was implanted into the human body at a site with no inflammation and thus low HNE activity. Even after the surface SATO groups are consumed, the hydrogel still maintained the capability to release H₂S when triggered. Upon an increase in HNE levels due to inflammation, the hydrogel can resume H₂S release to treat the disease (blue curve). Thus, the responsiveness of this hydrogel highlights its potential for treating chronic diseases with recurring inflammation.

Beyond its responsiveness to HNE, we also envisioned that the hydrogel modulus could be tuned by changing the ratio of PEG to CMC. We hypothesized that more CMC in the CMC/PEG mixture would increase the hydrogel crosslinking density because of the higher number of reactive carboxylic acid groups on CMC relative to PEG. We expected that higher crosslinking densities and increased stiffness would lead to a slower response to HNE, as well as different H₂S-release profiles.

To test this hypothesis, we prepared two more hydrogels with 55 and 75 mol% CMC (carboxylate count). Rheology frequency sweep experiments showed a trend that higher % CMC in the CMC/PEG mixture led to higher G' (at low frequency, G' values of hydrogels with 55 and 75 % CMC were 1900 and 3400 Pa, respectively), indicating a higher crosslinking density with more CMC (Fig. S2).²⁹ After reaction with SBTHA to install SATOs, elemental analysis showed sulfur wt% values of 1.70, 1.35 and 0.44% for hydrogels with 35, 55 and 75% CMC, respectively. Therefore, gel stiffness affected conversion in the SATO formation reaction, resulting in lower SATO loadings for stiffer gels.

Increasing the CMC composition from 35 % to 55 and 75 % also affected the H₂S release peaking concentration and time (Fig. 2B) in experiments with Cys and HNE. Consistent with lower SATO loadings for stiffer gels, peaking concentrations decreased from 0.8 ± 0.2 μ M, to 0.4 ± 0.1 , and 0.24 ± 0.04 μ M, respectively. The peaking time also decreased, from 354 ± 4 min (35% CMC) to 187 ± 7 min (55% CMC), while the peaking time of hydrogel with 75% CMC was difficult to determine because the trace reached a plateau near 0.24 μ M soon after the test began.

Finally, we evaluated the 35% CMC hydrogel in a biological assay. Our group has demonstrated the protective effects of H₂S against Dox toxicity and oxidative stress.^{28,30,31} Dox, a widely used chemotherapeutic, can cause serious inflammation by damaging intestinal and mucosal barriers, inducing systemic inflammation in cancer patients treated with the drug.³² Dox also upregulates cytokines under diabetic conditions, increasing the proinflammatory microenvironment in skeletal muscles.³³ These Dox-induced inflammatory responses also induce neutrophil production,^{34,35} which increases HNE levels. Given these deleterious effects of Dox, we hypothesized that our HNE-responsive, H₂S-releasing hydrogel could show protective effects under conditions mimicking Dox-induced inflammation.

To test this hypothesis, H9C2 rat embryonic cardiomyocytes were pretreated for 1 h with 35% CMC H₂S-releasing hydrogel or controls, then Dox was added to each treatment group without removing the hydrogel or other additives. The cells were incubated for another 24 h before analysing viability. As shown in Fig. 3, 5 μ M Dox was toxic, reducing the H9C2 viability to less than 60% compared with an untreated control group. Excitingly, H₂S-releasing pretreatment groups (Gel+Cys+HNE and Gel+Cys) displayed cell viabilities of 91% and 81%, respectively. These results indicated that the H₂S-releasing hydrogel rescued H9C2 cells from Dox toxicity with or without HNE, but the effect was statistically greater with added HNE. To ensure that the protective effects were from the H₂S release, several control pretreatments were tested (HNE, Cys, Gel, Gel+HNE, and Cys+HNE), none of

which released substantial amounts of H₂S. All non H₂S-releasing control groups showed low cell viabilities similar to that of the Dox only group.

In summary, in this addition to the field of H₂S-releasing materials,^{36,37} we have designed and synthesized an HNE-responsive H₂S-releasing hydrogel. With more enzyme, the hydrogel released more H₂S (higher peaking concentration) over longer times (greater peaking time). The results suggest that two types of SATO groups are present in the hydrogel: SATO groups on the surface of the hydrogel that can easily react with Cys, and SATO groups buried inside the hydrogel, which are only exposed to Cys and release H₂S when the enzyme degrades the crosslinks. Based on the observed cytoprotective effect against Dox from the HNE-responsive hydrogel, we envision the potential to use HNE-responsive, H₂S-releasing hydrogels to treat chronic inflammation, where responsive materials capable of long-term H₂S delivery at the inflammatory site may reduce inflammation and related symptoms.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the National Institutes of Health (R01GM123508), and the National Science Foundation (DMR-1454754). We thank Ryan Carrazzone and Prof Ronit Bitton for critically reading the manuscript and Dr Keith Ray for assistance with MALDI-TOF. Mass spectrometry resources are maintained by the Virginia Tech Mass Spectrometry Incubator, operated in part by the Virginia Tech Fralin Life Science Institute.

Notes and references

1. Abe K and Kimura H, J. Neurosci, 1996, 16, 1066–1071. [PubMed: 8558235]
2. WANG R, FASEB J., 2002, 16, 1792–1798. [PubMed: 12409322]
3. Lefer DJ, Proc.Natl.Acad.Sci USA, 2007, 104, 17907–8. [PubMed: 17991773]
4. Szabó C, Nat. Rev. Drug Discovery, 2007, 6, 917–935. [PubMed: 17948022]
5. Szabó C and Papapetropoulos A, Br J Pharmacol, 2011, 164, 853–865. [PubMed: 21198548]
6. Zanoardo RCO, Brancalione V, Distrutti E, Fiorucci S, Cirino G and Wallace JL, FASEB J., 2006, 20, 2118–2120. [PubMed: 16912151]
7. Shen Y, Shen Z, Luo S, Guo W and Zhu YZ, Oxid Med Cell Longev, 2015, 2015, 925167. [PubMed: 26078822]
8. Katsouda A, Bibli S-I, Pyriochou A, Szabo C and Papapetropoulos A, Pharmacol. Res, 2016, 113, 175–185. [PubMed: 27569706]
9. Wu D, Luo N, Wang L, Zhao Z, Bu H, Xu G, Yan Y, Che X, Jiao Z, Zhao T, Chen J, Ji A, Li Y and Lee GD, Sci. Rep, 2017, 7, 455. [PubMed: 28352125]
10. Casalini ED, Goodwill AG, Owen MK, Moberly SP, Berwick ZC and Tune JD, Microcirculation, 2014, 21, 104–111. [PubMed: 24033762]
11. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Pyriochou A, Roussos C, Roviezzo F, Brancalione V and Cirino G, Arter. Thromb. Vasc. Biol, 2010, 30, 1998–2004.
12. Zhao W, Zhang J, Lu Y and Wang R, EMBO J., 2001, 20, 6008–6016. [PubMed: 11689441]
13. Bhatia M, Scientifica, 2012, Article ID 159680.
14. Wang Z, Yin X, Gao L, Feng S, Song K, Li L, Lu Y and Shen H, SpringerPlus, 2016, 5, 1084. [PubMed: 27468384]
15. Wallace JL, Caliendo G, Santagada V, Cirino G and Fiorucci S, Gastroenterology, 2007, 132, 261–271. [PubMed: 17241876]

16. Zhang HX, Liu SJ, Tang XL, Duan GL, Ni X, Zhu XY, Liu YJ and Wang CN, *Cell. Physiol. Biochem.*, 2016, 40, 1603–1612. [PubMed: 28006762]
17. Hu Q, Katti PS and Gu Z, *Nanoscale*, 2014, 6, 12273–12286. [PubMed: 25251024]
18. Zelzer M, Todd SJ, Hirst AR, McDonald TO and Ulijn RV, *Biomater. Sci.*, 2013, 1, 11–39.
19. Ulijn RV, *J. Mater. Chem.*, 2006, 16, 2217–2225.
20. Allan EK, Holyoake TL and Jørgensen HG, *Leukemia*, 2006, 20, 2054–2055. [PubMed: 17008889]
21. Ohbayashi H, *Expert. Opin. Inv. Drug*, 2002, 11, 965–980.
22. Aimetti AA, Tibbitt MW and Anseth KS, *Biomacromolecules*, 2009, 10, 1484–1489. [PubMed: 19408953]
23. Kamarun D, Zheng X, Milanesi L, Hunter CA and Krause S, *Electrochim. Acta*, 2009, 54, 4985–4990.
24. Carter JM, Qian Y, Foster JC and Matson JB, *Chem. Comm.*, 2015, 51, 13131–13134. [PubMed: 26189449]
25. Qian Y, Kaur K, Foster JC and Matson JB, *Biomacromolecules*, 2019, 20, 1077–1086. [PubMed: 30676716]
26. Varaprasad K, Raghavendra GM, Jayaramudu T, Yallapu MM and Sadiku R, *Mater.Sci Eng.C*, 2017, 79, 958–971.
27. Foster JC, Powell CR, Radzinski SC and Matson JB, *Org. Lett.*, 2014, 16, 1558–1561. [PubMed: 24575729]
28. Wang Y, Kaur K, Scannelli SJ, Bitton R and Matson JB, *J. Am. Chem. Soc.*, 2018, 140, 14945–14951. [PubMed: 30369241]
29. Shmidov Y, Zhou M, Yosefi G, Bitton R and Matson JB, *Soft Matter*, 2019, 15, 917–925. [PubMed: 30644510]
30. Powell CR, Dillon KM, Wang Y, Carrazzone RJ and Matson JB, *Angew. Chem. Int. Ed.*, 2018, 57, 6324–6328.
31. Wang Y and Matson JB, *ACS Appl. Bio Mater*, 2019, 2, 5093–5098, DOI: 10.1021/acsabm.9b00768.
32. Wang L, Chen Q, Qi H, Wang C, Wang C, Zhang J and Dong L, *Cancer Res.*, 2016, 76, 6631–6642. [PubMed: 27680684]
33. Supriya R, Tam BT, Pei XM, Lai CW, Chan LW, Yung BY and Siu PM, *Front. Physiol.*, 2016, 7, 323. [PubMed: 27512375]
34. Krysko DV, Kaczmarek A, Krysko O, Heyndrickx L, Woznicki J, Bogaert P, Cauwels A, Takahashi N, Magez S, Bachert C and Vandenabeele P, *Cell Death Differ.*, 2011, 18, 1316–1325. [PubMed: 21311566]
35. Kaczmarek A, Krysko O, Heyndrickx L, Løve Aaes T, Delvaeye T, Bachert C, Leybaert L, Vandenabeele P and Krysko DV, *Cell Death Dis.*, 2013, 4, e961. [PubMed: 24336081]
36. Urquhart MC, Ercole F, Whittaker MR, Boyd BJ, Davis TP and Quinn JF, *Polym. Chem.*, 2018, 9, 4431–4439.
37. Kaur K, Carrazzone R and Matson JB, *Antioxid. Redox Signal*, 2020, 32, 79–95, DOI: 10.1089/ars.2019.7864. [PubMed: 31691577]

Fig. 1. H₂S-release profiles of hydrogels crosslinked with (A) HNE-degradable peptide **FBA-VKVVKV** and (B) non HNE-degradable peptide **FBA-GKGKGK**. SBTHA was added to both hydrogels to install SATO units. H₂S release experiments were performed by adding Cys (18 mM), HNE (1 HNE and 2 HNE correspond to 23 μg/mL and 46 μg/mL HNE, respectively) and PBS buffer to the gel and monitoring H₂S concentration over time.

Fig. 2. H_2S -release profiles for 35% CMC hydrogel. (A) First 24 h without HNE (black curve), followed by addition of fresh Cys and 2 HNE (blue curve) and Cys (18 mM) alone as control (pink curve); (B) H_2S release profiles for hydrogels with various % of CMC treated with Cys (18 mM) and 1 HNE.

Fig. 3.

Cell viability of H9C2 cardiomyocytes with different pretreatments (1 h) followed by exposure to Dox (5 μ M) for 24 h. Pretreatment conditions: **Dox**: No pretreatment; **Gel+Cys+HNE+Dox**: gel (166 μ M SATO groups), Cys (640 μ M), HNE (8 μ g/mL); **Gel+Cys+Dox**: gel (166 μ M SATO groups), Cys (640 μ M); **HNE+Dox**: HNE (8 μ g/mL); **Cys+Dox**: Cys (640 μ M); **Gel+Dox**: gel (166 μ M SATO groups); **Gel+HNE+Dox**: gel (166 μ M SATO groups), HNE (8 μ g/mL); **Cys+HNE+Dox**: Cys (640 μ M), HNE (8 μ g/mL). Cell viability was measured by CCK-8. Error bars indicate standard deviations, and group comparisons were determined by a one-way analysis of variance (ANOVA) and Tukey-Kramer HSD tests (n=5, ns = not significant vs Dox; * = $p < 0.01$ vs Dox; # = $p < 0.01$ vs Gel+Cys+Dox).

Scheme 1.

Synthetic route to H_2S -releasing polymer gels. Red bonds indicate HNE cleavage sites.